Astraea, an AI-native platform, is revolutionizing clinical trials by automating biostatistical workflows, significantly reducing the drug approval cycle. The platform processes raw clinical data, trial protocols, and study metadata to produce FDA-ready outputs in compliance with CDISC standards. Traditionally, these processes take nine months and require a team of 5–10 people, but Astraea accomplishes this in just a few days. Currently, the platform is focused on oncology and rare disease research. Co-founded by Stanford alumni Joshua Wang and Sanmay Sarada, Astraea has garnered support from Y Combinator. The platform's efficiency in generating SDTM and ADaM datasets, along with TFLs, is transforming the landscape of clinical trials, offering a faster path to drug approval.